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Abstract
Background: Extracellular matrix protein 1 (ECM1) is a glycoprotein involved in many biologic processes.
To determine the expression of ECM1 in hepatocellular carcinoma (HCC), and to study the role of ECM1 in
inducing epithelia-mesenchymal transition (EMT) to analyze the effect of ECM1 on the migration and invasion
of HCC cells.
Methods: The expression of ECM1 in HCC specimens was examined by immunohistochemistry staining, and the
correlations were analyzed between the expression of ECM1 and the clinicopathological data. The ECM1 expression
plasmid was transfected into Bel-7402 cells to induce exogenous overexpression of ECM1 protein. The changes of the
expression of ECM1, EMT-related protein (E-cadherin, Vimentin), in Bel-7402 cells were detected by Western blot after
transfection of ECM1; the wound healing and invasion assay in vitro were used to determine the role of ECM1 gene
transfection on the ability of migration and invasive potential of Bel-7402 cells.
Results: Immumohistochemistry staining method displayed the ECM1 expression was positively associated with vascular
invasion, TNM stage, and poor prognosis. A significant positive correlation was found between the expressions of ECM1
and Vimentin. After ECM1 overexpression, Western blot exhibited that the expression of E-cadherin was down-regulated
and Vimentin expression was up-regulated in Bel-7402 cells; the wound healing and invasion assay showed that the
migration and invasion potentials of Bel-7402 cells were significantly enhanced.
Conclusions: ECM1, which displayed a high expression in HCC specimens, was closely associated with clinicopathologic
data and may promote migration and invasion of HCC cells by inducing EMT.
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Background
Hepatocellular carcinoma (HCC) is the sixth most com-
mon malignancy and the third leading cause of cancer-
related death in the world with about 600 thousands
deaths each year [1]. Till now, curative surgical resection
of HCC remains the most effective therapy. Because of
high rate of metastasis and recurrence after surgery, the
prognosis of HCC remains dismal with 25–39 % survival
of patients in 5 years [2]. Therefore, better understandings
of the molecular mechanisms that contribute to HCC
invasion and metastasis are critically needed.
Some phenotypic changes and molecular events are
involved in cancer cell disintegration and migration into
distant organs or tissues. The epithelial-to-mesenchymal
transition (EMT), which is characterized by the down-
regulation or loss of epithelial markers (E-cadherin) and
up-regulation of mesenchymal markers (Vimentin), is a
crucial step in tumor invasion and metastasis [3–5].
Extracellular matrix protein 1 (ECM1), originally iden-
tified in 1994 as an 85 kDa glycoprotein was secreted
from osteogenic mouse stromal cell line MN7 that is
established from the bone marrow stroma of an adult
mouse [6, 7]. Presently, a number of studies have indicated
that ECM1 is involved in various biological processes,
such as mineralization, cell proliferation, angiogenesis,
and skin diseases [8–15]. In most cancers, ECM1 was
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found to promote cancer progression and invasion, and
overexpression of ECM1 has been identified as an indi-
cator of poor prognosis [10, 16–22]. Nevertheless, there
are few previous studies on the role of ECM1 in HCC
and EMT.
The current study is designed to evaluate the role of
ECM1 expression in HCC and to elucidate the associ-
ation with clinicopathological characteristics and prog-
nosis of HCC. First, the expression of ECM1 in HCC
tissues was detected using immunohistochemistry in a
hospital-based cohort of patients. Next, we used the
ECM1 expression plasmid transfect into Bel-7402 cells,
to explore the association of ECM1 expression among
E-cadherin and Vimentin.
Methods
Patients and tissue samples
One hundred and twenty patients with HCC who under-
went curative surgical resection between 2008 and 2012
at the Provincial Hospital of Anhui Medical University
were included. No patient received adjuvant therapy be-
fore surgery. These patients comprised of 93 males and 27
females, with mean age of 50.2 years (range: 21–73 years).
All included patients were staged according to the sixth
edition of the tumor-node-metastasis (TNM) classification
of the International Union against Cancer. Tumor dif-
ferentiation was defined according to the Edmondson
grading system. All tissue diagnoses were confirmed by
permanent histology. Seventeen samples of normal liver
tissues were acquired surgically from the patients who
had received an operation due to liver trauma. The in-
stitutional Ethics Committee of AnHui Provincial Hos-
pital approval for the project was achieved before the
initiation of the study. Informed consent was obtained
from each patient, and the study was in compliance with
the Helsinki Declaration. These patients comprised of 11
males and 6 females, with mean age of 52 years (range:
19–70 years). The clinical characteristics of these patients
have no significant difference between tumor patients.
The complete follow-up data were obtained from all
patients. The patients were followed up until January
1, 2015. The mean follow-up was 28.4 months (range,
3–71 months). All patients were prospectively moni-
tored using α-fetoprotein (AFP), abdominal ultrasonog-
raphy, and chest X-ray every 3–6 months after surgery.
Computed tomography and/or magnetic resonance im-
aging were used if necessary. The overall survival (OS)
was defined as the interval between the surgery and the
death of patients or the last follow-up. The data were cen-
sored at the last follow-up for living patients. Disease-free
survival (DFS) was measured from the date of surgery to
the HCC recurrence or the last follow-up. In the DFS
analysis, the data were censored for patients without
tumor recurrence (Additional file 1).
Cells and cell culture
The hepatocellular carcinoma cell line Bel-7402 was pur-
chased from the Liver Cancer Institute of Zhongshan
Hospital, Shanghai, China. The cells were routinely grown
as monolayers in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco BRL, New York, NY, USA) with 10 %
(vol/vol) fetal bovine serum (Hyclone, Logan, UT, USA),
100 U/ml penicillin, and 100 U/ml streptomycin at 37 °C
in a humidified incubator containing 5 % CO2.
Immunohistochemical staining reagents
Rabbit anti-ECM1 antibody and mouse anti-Vimentin
antibody were purchased from Proteintech Group Inc
(USA). Horse-radish peroxidase-conjugated secondary
antibody, phosphate-buffered saline (PBS), and 3,3-di-
aminobenzidine tetrahydrochloride (DAB) were obtained
from Beijing Zhongshan Golden Bridge Biotechnology
Company (China).
Immunohistochemical staining and evaluation
Tissue specimens were promptly fixed in 10 % neutral
formalin, embedded in paraffin, and cut into 3-μm sec-
tions. Immunohistochemical staining was carried out fol-
lowing the manufacturer’s instructions. Briefly, all sections
were gradually deparaffinized with xylene and alcohol.
The slides were processed with antigen retrieval by being
boiled in citrate buffer (pH 6.0) for 20 min and then
cooled down at room temperature. Subsequently, the
slides were incubated in a 10 % hydrogen peroxide so-
lution for 15 min to eliminate endogenous peroxidase
activity. The sections were then immunostained with
primary antibody of rabbit anti-ECM1 antibody (11521-
1-AP, Proteintech Group, USA) and mouse anti-Vimentin
antibody (ZM-0260, ZBGB-BIO) at 4 °C overnight. After
rinsing with PBS for 5 min, the sections were incubated in
horse-radish peroxidase (HRP)-conjugated secondary anti-
body (PV-6000, ZSGB-BIO) for 20 min. Being washed
again, peroxidase activity was visualized using freshly
prepared DAB (ZLI-9017, ZBGB-BIO) and then coun-
terstained lightly with Harris hematoxylin. The negative
controls were processed in a similar manner with PBS
instead of primary antibody.
ECM1 and Vimentin were mainly located in the cyto-
plasm of tumor cells. The intense of immunohisto-
chemistry staining was quantified by the percentage of
positive-staining cells. The positive-staining cell <10 %
was clarified as negative (−), and ≥10 % was positive
(+). Ten fields were selected, and expression in 1000
tumor cells (100 cells/field) was evaluated using a high
power (×400) of microscope. The immunohistochemi-
cal results were scored by three experienced patholo-
gists, who were blinded to clinical data.
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Construction of ECM1 expression vector
Taking the cDNA of human placenta tissue as the tem-
plate, RT-PCR amplification was performed and then
cloned into pEGFP-N2 vector. It was sequenced to obtain
the complete coding sequence of ECM1. The pEGFP-N2
plasmid (Invitrogen) was connected with the fragments of
target gene after the amplification of ECM1. The double
endonuclease restriction of BamH I and Xho I was per-
formed and purified, respectively. The plasmid and
fragments of target gene were recovered, which were
connected with T4 DNA ligase and then cultured in
LB flat plate that contained the ampicillin. The positive
clone was selected and sequenced to prove the suc-
cessful construction of eukaryotic expression vector
pEGFP-N2-ECM1.
Western blotting assays
Cultured cells in an exponentially growing phase and fro-
zen tissue samples were extracted with 1 ml of lysis buffer.
The protein concentration of the lysate was determined by
the BCA method (KeyGen, China). The extracts containing
approximately 30 μg of protein were loaded onto 10 % so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE), electrophoresed, and then transferred to
polyvinylidence difluoride (PVDF) membranes (Immo-
bilon-P. 0.45 μm, Millipore Corp., Bedford, MA, USA).
The membranes were blocked with 5 % skimmed milk
in PBST (phosphate-buffered saline with 0.1 % Tween 20)
for 1 h and then incubated with primary antibody of rabbit
anti-ECM1 antibody (Protein Group Inc, USA), rabbit
anti-Vimentin antibody (ab92574, Abcam, USA), rabbit
anti-E-cadherin antibody (ab15148, Abcam, USA), and
rabbit anti-β-actin (ab133626, Abcam, USA) antibody at
4 °C overnight. After being washed three times with PBST
buffer, the membranes were incubated with secondary
peroxidase-conjugated antibody (ZB-2308, ZSGB-BIO) for
1 h at room temperature. After being washed three more
times, the protein bands were detected by enhanced
chemiluminescence (Pierce, Rockford, USA) according
to the manufacturer’s instruction. β-actin antibody was
served as a control to confirm equal loading. Densi-
tometry index analysis of the bands was made using
gel imagery system.
Cell migration and invasion assays
Cell migration was assayed in a transwell chamber
with 24-well, 8.0-mm pore polycarbonate membrance
(Corning, USA). The same membranes were precoated
with matrigel (BD Biosciences, USA) for cell invasion
assay. Briefly, 100 μl 1 mg/ml matrigel solution was
added to the upper chamber, and then plate was im-
mediately inverted and gelled at 37 °C for 30 min in
an incubator. After 72-h transfection, cells were digested
and resuspended to a concentration of 1.0 × 105/ml using
serum-free DMEM with 0.1 % bovine serum albumin.
Two hundred-milliliter cell suspensions were seeded in
the upper chamber and filled the lower chamber with
500-ml complete DMEM. The chamber was rinsed in PBS
24 h after incubation and stained with 0.1 % crystal violet
for 15 min. The cells were counted using a light micro-
scope (magnification ×200). Migrated cells were averaged
from five fields per one chamber, and three chambers
were used on one experiment (Additional file 2).
Statistical analysis
All statistical analyses were performed using the statis-
tical package SPSS 13.0 (SPSS Inc., Chicago, IL). Fisher’s
exact test and the χ2 test were performed to assess asso-
ciations between ECM1 expression and clinicopathologi-
cal parameters. The Kaplan-Meier method was used for
Fig. 1 a Positive immunostainings for ECM1 in HCC tissues. b Positive immunostainings for Vimentin in HCC tissues. Both ECM1 and Vimentin
mainly expressed in the cytoplasm of HCC cells. Serial sections of tumor samples were made into 3-μm sections. Original magnification at ×200
Table 1 Expression of ECM1 in HCC and normal liver tissues
Cases ECM1
− + χ2 P
HCC 120 32 88 16.745 <0.001
Normal 17 13 4
P value was generated by comparing all subgroups and analyzed by the
chi-square test. P < 0.05 was considered as statistically significant
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survival analysis, and differences in survival were esti-
mated using the log-rank test. A multivariate survival
analysis was performed for all parameters that were
significant in the univariate analyses using the Cox re-
gression model. The correlation between ECM1 and
Vimentin was determined using Spearman rank correl-
ation coefficient. The difference of ECM1 protein ex-
pression levels among cell lines was examined by using
Student t test. A P value <0.05 was considered statisti-
cally significant.
Results
Immunohistochemical expression of ECM1 in HCC and
normal liver tissues
Immunohistochemical analysis revealed that both ECM1
staining was found in the cytoplasm (Fig. 1). ECM1 was
detected in 73.3 % (88/120) of HCC tissues, while 23.5 %
(4/17) in the normal liver tissues, respectively. The expres-
sion of ECM1 in HCC tissues was significantly higher than
that in normal liver tissues (P < 0.01) (Table 1).
We evaluated the association between ECM1 expression
and clinicopathological characteristics, including age, gen-
der, tumor size, number of tumor nodules, tumor capsule,
HBsAg status, serum AFP level, Edmondson’s grade, vas-
cular invasion, Child-Pugh class, stage of liver cirrhosis,
and TNM stage. ECM1 was significantly associated with
TNM stage (P = 0.049) and venous invasion (P = 0.030).
The expression of ECM1 was not associated with gender,
age, HBsAg status, Child-Pugh class, tumor capsule, and
AFP level (Table 2).
Correlation with ECM1 and Vimentin expression in HCC
Vimentin is an important hallmark of EMT, and high ex-
pression of Vimentin was also observed mainly in the
cytoplasmic staining. ECM1 and Vimentin expression was
positive in 88 (73.3 %) and 71 (59.1 %) cases, respectively.
Additionally, ECM and Vimentin were co-positive in 66
(55.0 %) cases. Using the Spearman rank test, the
immunostaining expression of ECM1 was positively
correlated with Vimentin expression in the HCC tis-
sues (r = 0.534, P < 0.001) (Table 3).
The impact of ECM1 expression on HCC prognosis
As was shown in Fig. 2, ECM1 was significantly associ-
ated with poor OS and DFS of HCC obtained by the
Kaplan-Meier method using the log-rank test. In addition,
Table 2 Correlation between the expression of ECM1 in 120
HCC tissues and their clinicopathological characteristics
Characteristics Case ECM1
− + χ2 P
Age (year) 0.001 0.978
≤50 56 15 41
>50 64 17 47
Gender 0.156 0.692
Male 93 24 69
Female 27 8 19
Nodule 0.002 0.967
Single 89 26 63
Multiple 31 6 25
Tumor size (cm) 0.477 0.490
≤5 65 19 46
>5 55 13 42
AFP (ng/ml) 0.477 0.490
≤400 55 13 42
>400 65 19 46
Tumor capsule 0.441 0.507
Well 66 16 50
Poorly 54 16 38
Edmondson’s grade 2.965 0.085
I/II 52 18 34
III/IV 68 14 54
HBsAg 1.108 0.293
Positive 104 26 78
Negative 16 6 10
Child-Pugh class 0.010 0.921
A 93 25 68
B 27 7 20
Vascular invasion 4.733 0.030
Absent 83 27 56
Present 37 5 32
Liver cirrhosis 2.472 0.291
Without/mild 67 21 46
Moderate 38 9 29
Severe 15 2 13
TNM stage 6.028 0.049
I 64 23 41
II 31 5 26
III 25 4 21
P value was generated by comparing all subgroups and analyzed by the
chi-square test. P < 0.05 was considered as statistically significant
Table 3 The correlation between ECM1 and Vimentin expression
in HCC tissues
Vimentin ECM1 rs P
Negative Positive
Negative 27 22 0.534 <0.001
Positive 5 66
P value was generated by determined using the Spearman rank correlation
coefficient. P < 0.05 was considered as statistically significant
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the survival benefits were also found in patients with earlier
TNM stage, absence of vascular invasion, single nodule,
smaller tumor size, well differentiation, intact tumor cap-
sule, and mild liver cirrhosis; in contrast, other parameters
did not predict HCC prognosis (Table 4). Multivariate
survival analysis enrolled above mentioned significant pa-
rameters and was performed using Cox regression. Results
revealed that ECM1 expression, tumor size, number of
tumor nodules, tumor capsule, vascular invasion, and liver
cirrhosis were the independent prognostic factors for
both OS and DFS in HCC patients after curative resec-
tion (P < 0.05) (Table 5).
Effect of ECM1 on expression of E-cadherin and Vimentin
protein in HCC cells
The ECM1 level of Bel-7402 cells was significantly in-
creased detected by immunohistochemical staining (Fig. 3).
As shown in Fig. 4, the increased expression of ECM1
could lead to the up-regulated expression of Vimentin
protein and down-regulated expression of E-cadherin pro-
tein in Bel-7402 cells. The relative quantity of three pro-
tein expressed levels in cells with significant difference
(ECM1: t = 12.909, P < 0.01; Vimentin; t = 10.564, P < 0.01;
E-cadherin:t = −8.558, P = 0.002).
ECM1 overexpression induces cell migration and invasion
To evaluate the role of ECM1 in the regulation of HCC
cells migration, we carried out a wound healing assay at
24 h post-infection. The wound healing assay revealed
that the migration rates of the cells in the Bel-7402
group infected with pEGFP-N2-ECM1 were significantly
increased compared with those without transfected group
(F = 110.592, P < 0.01 (Fig. 5). Subsequently, we assessed
the effect of ECM1 on cell invasion with a transwell assay.
Fig. 2 a Kaplan-Meier analysis of overall survival curve of HCC patients according to ECM1 expression. The HCC patients with ECM1-positive
showed significantly shorter overall survival survival rates than those with ECM1-negative. b Kaplan-Meier analysis of disease-free survival curve of
HCC patients according to ECM1 expression. The expression of ECM1 is associated with decreased disease-free survival rate
Table 4 Univariate survival analysis of OS and DFS in 120 patients with HCC
Characteristics OS DFS
HR 95 % CI P HR 95 % CI P
Age (>50 vs ≤50 years) 1.397 0.898–2.175 0.138 1.418 0.931–2.161 0.104
Gender (male vs female) 0.737 0.414–1.311 0.299 0.874 0.521–1.466 0.610
Nodule (multiple vs single) 3.254 2.005–5.280 <0.001 3.204 2.003–5.125 <0.001
Tumor size (>5 vs ≤5 cm) 3.747 2.374–5.913 <0.001 3.949 2.531–6.161 <0.001
Capsule (poorly vs well) 1.048 0.677–1.623 0.832 1.119 0.737–1.697 0.598
Liver cirrhosis (without/mild vs moderate/severe) 8.984 5.443–14.827 <0.001 9.798 5.955–16.119 <0.001
TNM stage (III vs I/II) 13.612 7.240–25.589 <0.001 12.074 6.480–22.500 <0.001
Edmondson’s grade (III/IV vs I/II) 1.471 0.932–2.321 0.098 1.377 0.895–2.120 0.146
Child-Pugh class (B vs A) 1.056 0.625–1.785 0.839 1.125 0.689–1.838 0.638
Vascular invasion (present vs absent) 22.957 11.683–45.112 <0.001 19.039 10.248–35.372 <0.001
AFP (>400 vs ≤400 ng/ml) 0.983 0.634–1.523 0.939 0.983 0.648–1.492 0.936
HBsAg (positive vs negative) 0.887 0.457–1.721 0.722 0.919 0.489–1.729 0.793
ECM1 (positive vs negative) 3.066 1.691–5.562 <0.001 2.294 1.360–3.872 0.002
P value was generated by univariate analyses using the Cox regression model. P < 0.05 was considered as statistically significant
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As shown in Fig. 6, compared with the control group, after
the up-regulated expression of ECM1, the number of in-
vading Bel-7402 cells was significantly increased (89.3 ±
2.5 cells/well vs 28.7 ± 2.5 cells/well). (t = 29.524, P < 0.01).
Discussion
Cytoplasmic ECM1 expression seems preferentially ex-
pressed in metastatic epithelial tumors, and it has been
observed in breast cancer, thyroid carcinoma, laryngeal
carcinoma, etc. [17, 18, 20, 21]. To date, little is known
about the association between ECM1 expression and clini-
copathological characteristics and prognosis of HCC. In
the present study, HCC patients with positive ECM1 ex-
pression had significantly poor survival rates, especially in
the subgroups of patients with invasive phenotypes, such
as those with advanced TNM stage and vascular invasion.
Using Cox multivariate regression analysis, ECM1 expres-
sion was an independent prognostic factor for OS and
DFS of HCC patients. Therefore, it was proposed that the
presence of ECM1 would be efficient for the prediction of
HCC metastasis and prognosis.
Although many studies have reported that ECM1 af-
fected not only the malignant cellular proliferation, but the
cancer cell migration and invasion, the exact mechanisms
by which ECM1 promoted tumor progression remained
unclear. HCC is one of the most common malignant tu-
mors in China, but few patients have chance to radical exci-
sion, postoperative recurrence rate is extremely high, and
migration and invasion are the main factors of recurrence
of HCC. In the migration of tumor involving a variety of
regulatory mechanism, EMT is one of the important mech-
anisms, which was first discovered at key transition steps
during embryogenesis and was the critical event that medi-
ated tumor metastasis [23]. EMT refers to the epithelial
cells in certain cases to the phenomenon of mesenchymal
cells; the main features for the loss of epithelial phenotype
and the get of mesenchymal phenotype result in heightened
cell motility and invasiveness through diminished cell–cell
and cell–matrix adhesion, reorganization of the cyto-
skeleton, and remodeling of the ECM [24–26]. Vimentin
has been recognized as a very important marker for EMT,
and its overexpression has been strongly associated with
metastatic phenotype and poor prognosis. More and more
evidence suggest that EMT plays an extremely important
role during the process of the spread of cancer of HCC
[27, 28].
Table 5 Multivariate survival analysis of OS and DFS in 120 patients with HCC
Characteristics OS DFS
HR 95 % CI P HR 95 % CI P
Nodule (multiple vs single) 2.482 1.417–4.348 0.001 1.961 1.140–3.373 0.015
Tumor size (>5 vs ≤5 cm) 2.009 1.144–3.529 0.015 2.529 1.464–4.369 0.001
Liver cirrhosis (without/mild vs moderate/severe) 6.879 2.964–15.968 <0.001 6.703 3.078–14.598 <0.001
Vascular invasion (present vs absent) 4.291 1.848–9.960 0.001 3.430 1.563–7.527 0.002
ECM1 (positive vs negative) 4.481 2.021–9.934 <0.001 3.289 1.601–6.758 0.001
P value was generated by multivariate survival analysis performed for all parameters that were significant in the univariate analyses using the Cox regression
model. P < 0.05 was considered as statistically significant
Fig. 3 a Representative pictures of ECM1 staining in Bel-7402 cells, ECM1 mainly expressed in the cytoplasm of cells. b Representative pictures of
ECM1 staining in ECM1-Bel-7402 cells. The ECM1 level of Bel-7402 cells was significantly increased detected by immunohistochemical staining.
Original magnification at ×200
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Primary studies have reported that ECM1 may pro-
mote EMT progression and increases the CSS pheno-
types through the stabilization of β-catenin protein by
MUC1 [29]. But whether ECM1 can promote migration
of HCC through the induction of EMT is unclear. This
experiment which mainly studies ECM1 in the role of
EMT-induced liver cancer metastasis further clarifies the
important effect of the migration in liver cancer inva-
sion. Our previous study suggests that ECM1 is over-
expressed in both HCC cells and tissues compared with
their benign counterparts [19]. On this basis, this re-
search transfects ECM1 into Bel-7402 HCC cell line,
Fig. 4 a Changes of ECM1 and EMT-related protein (E-cadherin and Vimentin) expression in Bel-7402 cells were detected by Western blot after
ECM1 transfection. The increased expression of ECM1 could lead to the up-regulated expression of Vimentin protein and down-regulated expression
of E-cadherin protein in Bel-7402 cells. b The relative quantity of three protein expressed levels in cells with significant difference (ECM1: t = 12.909,
P < 0.01; Vimentin; t = 10.564, P < 0.01; E-cadherin: t = −8.558, P = 0.002). Relative quantity of three protein expressed levels in cells. Data are mean ± SD
of three replicates. (P < 0.05)
Fig. 5 a Effect of ECM1 on the migration capacity of Bel-7402 cell by the wound healing assay at 24, 48, and 72 h (×40). b Statistics of analysis of
migration rate date in Bel-7402 and ECM1-Bel-7402 cells. The wound healing assay revealed that the migration rates of the cells in the Bel-7402
group infected with pEGFP-N2-ECM1 were significantly increased compared with those without transfected group (F = 110.592, P < 0.01). Data are
mean ± SD of three replicates. (P < 0.05)
Chen et al. World Journal of Surgical Oncology  (2016) 14:195 Page 7 of 9
induced by exogenous ECM1 expression. In this study,
we found that the up-regulated expression of ECM1 was
able to induce EMT. The expression of E-cadherin
significantly declined, and Vimentin was significantly in-
creased, which are very important markers for EMT,
suggesting that ECM1-Bel-7402 cells can be induced to
the occurrence of EMT. The tumor progression and
metastasis-inducing capability in vitro of HCC cell line
were also significantly enhanced, which is consistent
with previous findings in this study.
Conclusions
Comprehensive above research results, our study indi-
cated that the expression of ECM1 in HCC tissues was
significantly associated with invasive phenotypes of
HCC. ECM1 is a novel diagnostic marker for predicting
the prognosis of HCC patients, although further study with
a larger sample size was needed to confirm the current
findings. As a secretory glycoprotein, detection of serum
ECM1 level in HCC patients should be considered. We
also found that ECM1 could induce liver cancer cell migra-
tion by EMT, this may provide a new train of thought for
HCC effective diagnosis and treatment. But the intrinsic
mechanism of ECM1 promoting the migration of tumor is
very complex, and the induction of EMT may only be one
of these links; therefore, other mechanisms of ECM1 by
which in the process of HCC cell migration still need to be
further discussed.
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